

MUCOSAL VACCINES, ADJUVANTS & DELIVERY

12-14 November 2018, Lausanne, Switzerland

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR MUCOVAD 2018

Most pathogens access the body through the mucosal membranes. Therefore, effective vaccines that protect at these sites are an important requirement. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently launched. This is partly due to problems with developing safe and effective mucosal adjuvants. In the past decade, however, the successful development of live attenuated mucosal vaccines against influenza virus and rotavirus infections has boosted interest in this field, and the outlook for new mucosal vaccines looks to hold some promise.

There is therefore a major requirement to develop vaccines against many of the pathogens that infect mucosal tissues or have a mucosal port of entry. Parenteral vaccination may protect in some instances, but usually a mucosal vaccination route is necessary. Mucosal vaccines also have logistic advantages over injectable vaccines by being simpler to administer, having less risk of transmitting infections and potentially being easier to manufacture. Still, however, only relatively few vaccines for human use are available: oral vaccines against cholera, typhoid, polio, and rotavirus, and a nasal vaccine against influenza. For polio, typhoid and influenza, in which the pathogens reach the blood stream, there is also an injectable vaccine alternative. A problem with available oral live vaccines is their reduced immunogenicity when used in developing countries; for instance, the efficacy of rotavirus vaccines correlates closely with the national per capita income. Research is required to define the impact of factors such as malnutrition, aberrant intestinal microflora, concomitant infections, and pre-existing immunity as well as of host genetic factors on the immunogenicity of these vaccines.

MUCOVAD 2018 will be an opportunity for researchers to hear updates on new developments in the area of mucosal vaccines and associated adjuvantation and delivery mechanisms/platforms.

MUCOVAD 2018 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups.

SCIENTIFIC ADVISORY PANEL

Ted M. Ross (*University of Georgia, Athens, Georgia, USA*)
Jan Holmgren (*Gothenburg University, Gothenburg, Sweden*)
Edward Lavelle (*Trinity College Dublin, Dublin, Ireland*)
Eric Cox (*University of Ghent, Ghent, Belgium*)
Ali Harandi (*Gothenburg University, Gothenburg, Sweden*)
Dexiang Chen (*PATH, Seattle, Washington, USA*)

Rob Lambkin-Williams (*hVIVO, London, UK*)
Dennis Christensen (*Statens Serum Institut, Copenhagen, Denmark*)
Anna-Karin Maltais (*Eurocine Vaccines AB, Solna, Sweden*)
Sean Tucker (*Vaxart Inc., San Francisco, California, USA*)
Pearay L. Ogra (*University of Buffalo, Buffalo, New York, USA*)
Milton Maciel Jr. (*NMRC/WRAIR, Silver Spring, Maryland, USA*)

CONFERENCE SCOPE/TOPICS

Developmental aspects of mucosal environment and immunity

Lessons learned from earlier and existing (available) mucosal vaccines

Approaches to the development of modern mucosal vaccines/adjuvants and delivery systems

Considerations of the routes of immunization (sublingual, oral, nasal, rectal, vaginal, intrapulmonary, ocular),
antigens and genomics (different challenges at different mucosal sites)

Developmental aspects of human and veterinary mucosal vaccines/adjuvants currently in progress

Live vector vaccines/ Particle-based vaccines(including VLPs) /Conjugate vaccines

Delivery systems and formats – new and future developments
(conjugates/particles, liquids/sprays/dry powder/tablet/capsules/enteric coatings)

Regulatory and Safety requirements for mucosal vaccines/adjuvants

inovio
PHARMACEUTICALS

EUROCINE  VACCINES

 VAXART

hVIVO
better treatments, faster

DNAvaccine.com

NatureGeneTherapy.com
Gene-based vaccines

 **aldevron**

 **atrivax**

Abstract Submissions

The MUCOVAD 2018 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during MUCOVAD 2018. The one page abstract should contain sufficient information for the Advisory Scientific Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (MUCOVAD 2018 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: **Friday 20th July 2018**. Authors will be informed of the status of their contribution(s) in August 2018. Closing date for submissions intended for poster presentation: **Friday 26th October 2018**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to MUCOVAD 2018. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at MUCOVAD 2018. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- ☐ I wish to be placed on the mailing list to receive further information on MUCOVAD 2018
- ☐ I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

Intended session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please Type/Print):

- ☐ My organisation is interested in sponsoring MUCOVAD 2018 ☐ Please send me details of exhibition/delegate pack insert service

REQUEST DETAILS OF FUTURE EVENTS

- ☐ **MODERN VACCINES ADJUVANTS FORMULATION** – 2-4 May 2018, Leiden, The Netherlands
- ☐ **VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES** – 25-27 September 2018, Berne, Switzerland
- ☐ **PLANT-BASED VACCINES ANTIBODIES & BIOLOGICS** – 10-12 June 2019, University of Riga, Riga, Latvia

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, MUCOVAD 2018, MEETINGS MANAGEMENT
Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom
Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: jherriot@meetingsmgmt.u-net.com
Website: www.meetingsmanagement.com/mucovad_2018